About this trial
Depression is a leading cause of morbidity and mortality, conferring substantial healthcare and societal costs. By studying methods to non-invasively target neural circuitry involved in reward responsivity, information generated by this project will improve understanding of the circuit alterations that underlie motivation and pleasure deficits in depression, and could also lead to the development of biologically-based markers of neurostimulation-based treatment response.
Eligibility criteria
Qualifiers
All participants
18-65 years old
Normal (or corrected to normal) vision
Participants with MDD
Disqualifiers
Premorbid IQ estimate < 70
Past or present neurological problems (including seizures and head trauma resulting in neurological or cognitive sequelae)
Loss of consciousness > 30 minutes or any loss of consciousness with neurological sequelae
Major medical conditions (e.g., seizure disorders, treatment with anticonvulsant medication, endocrine disorders, significant cardiac pathology), or other physical conditions if they preclude participation in EEG, TMS, or MRI protocols (e.g. peripheral nerve damage, limb paralysis etc.)
Trial design
Treatments tested in this trial
- TMS: single session intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal target in individuals with major depressive disorder, via MagVenture MagPro R30 device / Cool-DB80 A/P coil
- SHAM (inactive) TMS stimulation